Press Releases 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Eagle Pharmaceuticals and Enalare Therapeutics Announce FDA Orphan Drug Designation for ENA-001 for the Treatment of Apnea of Prematurity, a New Chemical Entity Being Developed as an Agnostic Respiratory Stimulant 10/3/22 Eagle Pharmaceuticals and Enalare Therapeutics Announce Additional Award Worth Up to $50 Million from BARDA to Advance an Intramuscular (“IM”) Formulation of ENA-001 9/27/22 Eagle Pharmaceuticals to Present at the Morgan Stanley 20th Annual Global Healthcare Conference 8/30/22 Federal Circuit Rules in Favor of Eagle Pharmaceuticals in Vasopressin Litigation 8/18/22 Eagle Pharmaceuticals Reports Second Quarter 2022 Results 8/9/22 Eagle Pharmaceuticals Takes Equity Stake in, with Option to Acquire, Enalare Therapeutics to Advance Global Development of ENA-001, a Novel Agnostic Respiratory Stimulant 8/9/22 Eagle Pharmaceuticals to Host Second Quarter 2022 Financial Results on August 9, 2022 7/28/22 Eagle Pharmaceuticals Appoints Debra M. Hussain as SVP, Head of Commercial 7/18/22 Eagle Pharmaceuticals Completes Acquisition of Acacia Pharma Group plc, Expanding Acute Care Footprint 6/9/22 Eagle Pharmaceuticals Announces Submission of New Drug Application to U.S. Food and Drug Administration for Landiolol, a Beta-1 Adrenergic Blocker 6/1/22 Pagination First page Previous page Page 1 Current page 2 Page 3 Page 4 Next page Last page
